Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;66(12):4120-4127.
doi: 10.1007/s10620-020-06814-1. Epub 2021 Jan 21.

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

Dana M Harris  1 , Fernando F Stancampiano  2 , M Caroline Burton  3 , Ann M Moyer  4 , Michael J Schuh  5 , Jose R Valery  2 , Yan Bi  6
Affiliations
Review

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

Dana M Harris et al. Dig Dis Sci. 2021 Dec.

Abstract

Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical guidance on when to order pharmacogenomic testing, which test to order, and how to modify treatment based on published guidelines.

Keywords: Gastroesophageal reflux disease; Helicobacter pylori; Pharmacogenomics; Proton pump inhibitors.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Lima JJ, Thomas CD, Barbarino J et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.2015 . - DOI - PubMed
    1. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528–534 - DOI
    1. Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol. 2001;13:S43-47 - PubMed
    1. Dean L. Esomeprazole Therapy and CYP2C19 Genotype. 2012 Oct 1 [Updated 2019 Sep 23]. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda MD: National Center for Biotechnology Information (US); 2012. Available from: https://www.ncbi.nlm.nih.gov/books/NBK100896/ .
    1. Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24:334–344 - DOI

Substances

LinkOut - more resources